Comparing CVRx (NASDAQ:CVRX) and Vivos Therapeutics (NASDAQ:VVOS)

CVRx (NASDAQ:CVRX) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for CVRx and Vivos Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CVRx	0	1	6	0	2.86
Vivos Therapeutics	0	0	2	0	3.00

CVRx currently has a consensus target price of $17.83, indicating a potential upside of 57.82%. Vivos Therapeutics has a consensus target price of $6.30, indicating a potential upside of 95.05%. Given Vivos Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Vivos Therapeutics is more favorable than CVRx.

Insider and Institutional Ownership

75.3% of CVRx shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 18.9% of CVRx shares are held by company insiders. Comparatively, 3.0% of Vivos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares CVRx and Vivos Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CVRx	$51.29 million	5.74	-$59.97 million	($2.69)	-4.20
Vivos Therapeutics	$14.58 million	1.30	-$13.58 million	($5.68)	-0.57

Vivos Therapeutics has lower revenue, but higher earnings than CVRx. CVRx is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

CVRx has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.47, meaning that its share price is 647% more volatile than the S&P 500.

Profitability

This table compares CVRx and Vivos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CVRx	-116.91%	-93.06%	-51.78%
Vivos Therapeutics	-86.19%	-335.04%	-93.58%

Summary

CVRx beats Vivos Therapeutics on 8 of the 14 factors compared between the two stocks.

About CVRx

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.